Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa A Beck

Showing results (121-130 of 181) with videos related to

Pageof 19
Sort By:
The Journal of Allergy and Clinical Immunology|December 2, 2019
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trialEmma Guttman-Yassky, Diamant Thaçi, Aileen L Pangan, et al.
The Journal of Allergy and Clinical Immunology|December 31, 2003
Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromesJennifer K Garrett, Sean C Jameson, Blythe Thomson, et al.
Msphere|December 17, 2016
Temporal and Racial Differences Associated with Atopic Dermatitis <i>Staphylococcus</i><i>aureus</i> and Encoded Virulence FactorsJoseph A Merriman, Elizabeth A Mueller, Michael P Cahill, et al.
The Journal of Allergy and Clinical Immunology|May 15, 2010
Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticumPei-Song Gao, Nicholas M Rafaels, Deguang Mu, et al.
The Journal of Allergy and Clinical Immunology|April 15, 2011
Reductions in claudin-1 may enhance susceptibility to herpes simplex virus 1 infections in atopic dermatitisAnna De Benedetto, Mark K Slifka, Nicholas M Rafaels, et al.
Frontiers in Systems Neuroscience|February 15, 2021
Alterations of Spinal Epidural Stimulation-Enabled Stepping by Descending Intentional Motor Commands and Proprioceptive Inputs in Humans With Spinal Cord InjuryMegan L Gill, Margaux B Linde, Rena F Hale, et al.
American Journal of Clinical Dermatology|June 20, 2020
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic DermatitisLisa A Beck, Diamant Thaçi, Mette Deleuran, et al.
Advances in Therapy|April 18, 2026
Long-Term Dupilumab Treatment Is Not Associated with an Increased Overall Risk of Infections in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label 5-Year Extension StudyLisa A Beck, Eric L Simpson, Diamant Thaçi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 9, 2023
The vIGA-AD scale for atopic dermatitis: Uptake in the past 5 years and position of the International Eczema CouncilRobert Bissonnette, Eric Simpson, Lawrence F Eichenfield, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 19, 2023
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND studyKristian Reich, Jonathan I Silverberg, Kim A Papp, et al.
Pageof 19

Showing results (121-130 of 181) with videos related to

Sort By:
Pageof 19
The Journal of Allergy and Clinical Immunology|December 2, 2019
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trialEmma Guttman-Yassky, Diamant Thaçi, Aileen L Pangan, et al.
The Journal of Allergy and Clinical Immunology|December 31, 2003
Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromesJennifer K Garrett, Sean C Jameson, Blythe Thomson, et al.
Msphere|December 17, 2016
Temporal and Racial Differences Associated with Atopic Dermatitis <i>Staphylococcus</i><i>aureus</i> and Encoded Virulence FactorsJoseph A Merriman, Elizabeth A Mueller, Michael P Cahill, et al.
The Journal of Allergy and Clinical Immunology|May 15, 2010
Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticumPei-Song Gao, Nicholas M Rafaels, Deguang Mu, et al.
The Journal of Allergy and Clinical Immunology|April 15, 2011
Reductions in claudin-1 may enhance susceptibility to herpes simplex virus 1 infections in atopic dermatitisAnna De Benedetto, Mark K Slifka, Nicholas M Rafaels, et al.
Frontiers in Systems Neuroscience|February 15, 2021
Alterations of Spinal Epidural Stimulation-Enabled Stepping by Descending Intentional Motor Commands and Proprioceptive Inputs in Humans With Spinal Cord InjuryMegan L Gill, Margaux B Linde, Rena F Hale, et al.
American Journal of Clinical Dermatology|June 20, 2020
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic DermatitisLisa A Beck, Diamant Thaçi, Mette Deleuran, et al.
Advances in Therapy|April 18, 2026
Long-Term Dupilumab Treatment Is Not Associated with an Increased Overall Risk of Infections in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label 5-Year Extension StudyLisa A Beck, Eric L Simpson, Diamant Thaçi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 9, 2023
The vIGA-AD scale for atopic dermatitis: Uptake in the past 5 years and position of the International Eczema CouncilRobert Bissonnette, Eric Simpson, Lawrence F Eichenfield, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 19, 2023
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND studyKristian Reich, Jonathan I Silverberg, Kim A Papp, et al.
Pageof 19